Clinically Relevant Insights
Tests analyze risk variants identified from genome-wide studies of >150K patients with cardiometabolic disease.
A comprehensive genomic map of cardiometabolic risks.
MyOme Atlas Cardiometabolic uses whole-genome sequencing (WGS) to uncover holistic cardiometabolic risks and support proactive, personalized health decisions.
>1M
genetic risk factors analyzed
10-year
risk of developing disease reported
5–6 weeks
turnaround time from samples received
Blood or buccal
sample types accepted
What Atlas measures
Integrated Risk tests combine polygenic risk scores (PRS) from whole-genome sequencing with clinical inputs from a patient's health history to reveal cardiometabolic risks that traditional assessments may miss. MyOme PRS models have been shown to outperform existing clinical risk tools in detecting high-risk cases. As science advances and clinical profiles evolve, the same whole-genome dataset can be reanalyzed for new insights — no new sample required.
Actionable Reports
Results include clear metrics and next steps aligned with cardiometabolic guidelines.
Validated Cross-Ancestry Performance
Proprietary ancestry decomposition technology enables accurate risk prediction across diverse populations.
Why this matters
Uncover risks that standard assessments can miss.
~60%
of CAD and type 2 diabetes risk is due to heritable factors
Genetic risk that standard clinical calculators often don't consider.¹
~20%
of heart attacks occur in people with no standard clinical risk factors
Standard clinical assessments miss at-risk patients.²
1 in 10
high-risk patients missed by a standard CAD risk calculator* were identified by MyOme
Atlas catches hidden high-risk cases.³
1. Blumenthal RS, Morris PB, Gaudino M, et al. J Am Coll Cardiol. Published online March 13, 2026. 2. Mazhar J, Figtree G, Vernon ST, et al. Am J Prev Cardiol. 2020;4:100116. 3. Ratman D, Tshiaba P, Levin M, et al. npj Cardiovasc Health. 2025;2:13. *Standard CAD risk calculator refers to the ASCVD pooled cohort equation (PCE) tool.
Test Offerings
Proactive screening
Integrated Risk tests
Polygenic risk scores combined with clinical factors predict absolute risk for common, serious health conditions — often years before symptoms or measurable biomarkers arise.
Diagnostic testing
Monogenic Panels
Monogenic diagnostic panels identify disease-associated variants in a defined set of genes for patients with clinical risk factors or a family history of disease.
Dyslipidemia Dx
Coming Soon Reimbursable
Analyzes 14 genes associated with dyslipidemia and reports diagnostic variants identified. Includes the option to add six polygenic risk scores for related conditions and traits. Covered by most payers when medical-necessity criteria are met.
Ordering & logistics
Multiple test options offered
Atlas Cardiometabolic Plus
Leverages whole-genome sequencing for comprehensive insights across coding and non-coding regions, with re-analysis on the same sample as new scores launch.
Test codes
CADPR41016
Type 2 diabetesPR41027
Atlas Cardiometabolic Select
Uses high-coverage exome plus low-coverage whole-genome sequencing — a cost-effective option for preventative health decisions, with re-analysis on the same sample as new scores launch.
Test codes
CADPR42014
Type 2 diabetesPR42023
Turnaround times
From samples received, most results are delivered in 5 to 6 weeks. Follow-up testing or re-requisitions for existing MyOme patients are typically completed in under 2 weeks, often within a few days.
Sample Types Accepted
- Blood
- Buccal (cheek swab)
Genomic risk, mapped. Lifelong health, guided.
We're here at every step — from ordering and sample collection to interpreting results with your patients.